Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
INZ-701 by Inozyme Pharma for Arterial Calcification: Likelihood of Approval
INZ-701 is under clinical development by Inozyme Pharma and currently in Phase III for Arterial Calcification. According to GlobalData, Phase...
INZ-701 by Inozyme Pharma for Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome): Likelihood of Approval
INZ-701 is under clinical development by Inozyme Pharma and currently in Phase II for Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg...
INZ-701 by Inozyme Pharma for Rickets: Likelihood of Approval
INZ-701 is under clinical development by Inozyme Pharma and currently in Phase II for Rickets. According to GlobalData, Phase II...
INZ-701 by Inozyme Pharma for Calciphylaxis: Likelihood of Approval
INZ-701 is under clinical development by Inozyme Pharma and currently in Phase I for Calciphylaxis. According to GlobalData, Phase I...
INZ-701 by Inozyme Pharma for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD): Likelihood of Approval
INZ-701 is under clinical development by Inozyme Pharma and currently in Phase I for End-Stage Kidney Disease (End-Stage Renal Disease...
Risk adjusted net present value: What is the current valuation of Inozyme Pharma's INZ-701?
INZ-701 is a fusion protein commercialized by Inozyme Pharma, with a leading Phase III program in Arterial Calcification. According to...